Mission Statement, Vision, & Core Values (2026) of Beijing SL Pharmaceutical Co., Ltd.

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) has rapidly evolved since its founding in 2001 into a national pharmaceutical force, boasting a market capitalization of about ¥16.5 billion (Oct 2023) and generating ¥2.4 billion in revenue in 2023-a 15% year‑over‑year increase-while operating a retail footprint of over 2,000 pharmacies across 16 provinces, municipalities, and autonomous regions; driven by a mission to improve global health through innovation and safety, the company invested ¥400 million in R&D in 2023 (≈16.7% of revenue), collaborates with more than 50 research partners, has launched therapies for rare diseases and pediatric care, and embeds core values of innovation, integrity, cooperation, inclusiveness and responsibility into a vision that targets expanded accessibility, higher R&D intensity and a 25% reduction in carbon footprint through greener manufacturing and supply‑chain optimization.

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Intro

• Patient First - prioritize clinical benefit and safety in every product decision.
• Innovation - sustained investment in R&D and collaborative research to bring novel therapies to market.
• Integrity - compliance, transparent governance, and ethical conduct across the value chain.
• Quality & Safety - rigorous quality management from lab to patient.
• Sustainability - measurable environmental targets and responsible resource use.
• Collaboration - partnerships with research institutes, hospitals, and industry players to accelerate development.

• R&D allocation: ¥400 million in 2023 (16.7% of revenue) to biologicals, orphan diseases, pediatric formulations, and TCM modernization.
• Pipeline emphasis: orphan and pediatric drugs plus biologics and combination TCM-chemical therapies.
• Collaborations: strategic alliances with >50 academic and industrial research partners to accelerate translational research and clinical development.

• Nationwide reach through a retail network spanning 16 provinces, municipalities, and autonomous regions.
• Product mix includes biologicals, chemicals, TCM, nutrition & supplements, orphan and pediatric drugs to serve diverse patient needs.
• Distribution strategy leverages >2,000 retail pharmacies for broad primary care and chronic care access.

• Operational target: 25% carbon footprint reduction by 2025 via greener manufacturing technologies and optimized supply-chain logistics.
• Environmental actions: energy efficiency upgrades, waste reduction in production, and supplier engagement for lower-scope emissions.
• Governance: compliance with national regulations and reporting aligned with stakeholder transparency.

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Overview

Mission Statement

Beijing SL Pharmaceutical Co., Ltd. focuses on delivering innovative pharmaceutical products, driven by the mission to improve global health standards while ensuring unparalleled quality and safety in its offerings. The company leverages advanced biotechnology and translational research to provide effective treatments across oncology, cardiology, and infectious diseases, with particular attention to rare and underserved conditions.

• 2023 R&D investment: ¥400 million (16.7% of total revenue).
• Established collaborations with over 50 research entities and institutions.
• Launched three new therapies targeting rare diseases in 2022.
• Committed to reducing carbon footprint by 25% by 2025 through greener manufacturing and supply-chain optimization.

Vision

To become a globally respected biopharmaceutical leader that transforms patient outcomes through cutting‑edge science, scalable manufacturing, and equitable access to life‑saving therapies.

Core Values

• Patient‑Centricity - prioritize safety, accessibility, and measurable clinical benefit.
• Scientific Rigor - invest in robust preclinical and clinical evidence; maintain strict quality control.
• Collaboration - partner with academic institutions, biotech firms, and global health organizations.
• Sustainability - target a 25% carbon footprint reduction by 2025 via energy efficiency and greener processes.
• Integrity & Compliance - adhere to regulatory standards across domestic and international markets.

For a deeper look at the company's history, ownership, mission and business model, see Beijing SL Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Mission Statement

• Drive innovation via focused R&D investment: target 15% of revenue in 2023 (~¥300 million) and ramp to 20% by end-2024.
• Expand market reach by increasing distribution networks by 30% in underserved and remote regions by 2024.
• Implement sustainable manufacturing and sourcing to cut carbon footprint by 25% by 2024.
• Enhance organizational capability and culture to lift employee engagement scores by 15% by 2024 through training and development.

• Financial implication: allocating ~¥300 million to R&D in 2023 reflects a strategic trade-off toward long-term pipeline value and higher-margin specialty products.
• Operational implication: a 30% expansion in distribution requires logistics investments, cold-chain upgrades, and local partnerships.
• Sustainability implication: a 25% carbon reduction will involve capital expenditures in energy systems and supplier engagement to decarbonize inputs.

Beijing SL Pharmaceutical Co., Ltd. (002038.SZ) - Vision Statement

• Innovation - relentless investment in R&D to expand pipelines and optimize production processes;
• Integrity - adherence to ethical standards, regulatory compliance, and transparent reporting;
• Cooperation - building long-term partnerships with universities, CROs, hospitals, and global distributors;
• Inclusiveness - cultivating a diverse workforce and inclusive culture across functions and geographies;
• Responsibility - committing to environmental stewardship, public health initiatives, and patient-centric access programs.

• R&D intensity: sustained target of allocating 8-12% of annual revenue to R&D to accelerate novel drug discovery and lifecycle management of generics and biologics.
• Quality & compliance: maintain full compliance across all GMP-certified production sites and target zero critical compliance findings in external inspections.
• Global commercialization: expand export footprint and out-license agreements to increase overseas revenue share to a target of 20-30% within five years.
• ESG & corporate responsibility: reduce greenhouse gas emissions intensity and increase community health program reach by defined annual targets.

• Innovation: multi-year projects in biologics, oncology supportive care, and novel delivery systems; strategic allocation of capital to pilot plants and CRO collaborations.
• Integrity: strengthened internal controls, third-party audits, and publication of clinical-trial results to enhance transparency and stakeholder trust.
• Cooperation: formal alliances with top medical universities, co-development agreements with international partners, and hospital-based real-world evidence programs to speed up market access.
• Inclusiveness: talent programs, targeted recruitment to increase representation in R&D and leadership, and cross-functional rotation schemes to broaden capabilities.
• Responsibility: environmental investments (wastewater treatment upgrades, energy-efficiency retrofits), patient assistance programs, and charitable medical outreach in under-served regions.

• Annual R&D pipeline progression (preclinical → IND → NDA)
• Time-to-market for key launches (months from approval to first commercial sale)
• Regulatory inspection outcomes and product recall rates
• Revenue mix by domestic vs. international markets
• ESG metrics: emissions intensity, waste treatment rate, employee safety incidents